vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPagerDuty, Inc.（PD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $124.5M、PagerDuty, Inc.の約1.5倍）。PagerDuty, Inc.の純利益率が高く（129.7% vs 13.3%、差は116.4%）。PagerDuty, Inc.の前年同期比売上増加率が高い（4.7% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $24.1M）。過去8四半期でPagerDuty, Inc.の売上複合成長率が高い（5.9% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
PagerDutyはアメリカのクラウドコンピューティング企業で、IT運用部門向けのSaaS型インシデント管理プラットフォームを専門に手がけています。システム異常をリアルタイムで検知し、迅速な障害対応を支援することで、業務システムの安定稼働を支えるソリューションを提供しています。
AMPH vs PD — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $124.5M |
| 純利益 | $24.4M | $161.6M |
| 粗利率 | 46.8% | 85.3% |
| 営業利益率 | 19.4% | 6.5% |
| 純利益率 | 13.3% | 129.7% |
| 売上前年比 | -1.8% | 4.7% |
| 純利益前年比 | -35.7% | 2827.7% |
| EPS（希薄化後） | $0.51 | $1.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $124.5M | ||
| Q3 25 | $191.8M | $123.4M | ||
| Q2 25 | $174.4M | $119.8M | ||
| Q1 25 | $170.5M | $121.4M | ||
| Q4 24 | $186.5M | $118.9M | ||
| Q3 24 | $191.2M | $115.9M | ||
| Q2 24 | $182.4M | $111.2M | ||
| Q1 24 | $171.8M | $111.1M |
| Q4 25 | $24.4M | $161.6M | ||
| Q3 25 | $17.4M | $9.6M | ||
| Q2 25 | $31.0M | $-7.2M | ||
| Q1 25 | $25.3M | $-8.8M | ||
| Q4 24 | $38.0M | $-5.9M | ||
| Q3 24 | $40.4M | $-10.9M | ||
| Q2 24 | $37.9M | $-17.1M | ||
| Q1 24 | $43.2M | $-28.2M |
| Q4 25 | 46.8% | 85.3% | ||
| Q3 25 | 51.4% | 84.6% | ||
| Q2 25 | 49.6% | 84.0% | ||
| Q1 25 | 50.0% | 83.6% | ||
| Q4 24 | 46.5% | 83.0% | ||
| Q3 24 | 53.3% | 82.7% | ||
| Q2 24 | 52.2% | 82.6% | ||
| Q1 24 | 52.4% | 81.7% |
| Q4 25 | 19.4% | 6.5% | ||
| Q3 25 | 13.2% | 2.9% | ||
| Q2 25 | 24.2% | -8.6% | ||
| Q1 25 | 21.9% | -9.6% | ||
| Q4 24 | 24.2% | -8.7% | ||
| Q3 24 | 29.8% | -13.8% | ||
| Q2 24 | 30.3% | -19.5% | ||
| Q1 24 | 27.9% | -30.1% |
| Q4 25 | 13.3% | 129.7% | ||
| Q3 25 | 9.0% | 7.8% | ||
| Q2 25 | 17.8% | -6.0% | ||
| Q1 25 | 14.8% | -7.2% | ||
| Q4 24 | 20.4% | -5.0% | ||
| Q3 24 | 21.1% | -9.4% | ||
| Q2 24 | 20.8% | -15.4% | ||
| Q1 24 | 25.1% | -25.3% |
| Q4 25 | $0.51 | $1.69 | ||
| Q3 25 | $0.37 | $0.10 | ||
| Q2 25 | $0.64 | $-0.07 | ||
| Q1 25 | $0.51 | $-0.12 | ||
| Q4 24 | $0.74 | $-0.07 | ||
| Q3 24 | $0.78 | $-0.14 | ||
| Q2 24 | $0.73 | $-0.26 | ||
| Q1 24 | $0.81 | $-0.34 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $547.8M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $320.5M |
| 総資産 | $1.6B | $1.0B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $547.8M | ||
| Q3 25 | $276.2M | $567.9M | ||
| Q2 25 | $231.8M | $597.1M | ||
| Q1 25 | $236.9M | $570.8M | ||
| Q4 24 | $221.6M | $542.2M | ||
| Q3 24 | $250.5M | $599.3M | ||
| Q2 24 | $217.8M | $592.8M | ||
| Q1 24 | $289.6M | $571.2M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | $484.5M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $489.5M |
| Q4 25 | $788.8M | $320.5M | ||
| Q3 25 | $776.7M | $180.7M | ||
| Q2 25 | $757.5M | $145.7M | ||
| Q1 25 | $751.3M | $129.8M | ||
| Q4 24 | $732.3M | $111.6M | ||
| Q3 24 | $727.7M | $164.7M | ||
| Q2 24 | $713.3M | $174.0M | ||
| Q1 24 | $672.4M | $171.6M |
| Q4 25 | $1.6B | $1.0B | ||
| Q3 25 | $1.7B | $891.5M | ||
| Q2 25 | $1.6B | $926.8M | ||
| Q1 25 | $1.6B | $927.3M | ||
| Q4 24 | $1.6B | $866.8M | ||
| Q3 24 | $1.5B | $916.0M | ||
| Q2 24 | $1.5B | $924.0M | ||
| Q1 24 | $1.6B | $925.3M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 3.73× | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 2.85× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $24.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $24.1M |
| FCFマージンFCF / 売上 | 13.4% | 19.3% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.6% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 0.15× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $117.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $24.8M | ||
| Q3 25 | $52.6M | $34.0M | ||
| Q2 25 | $35.6M | $30.7M | ||
| Q1 25 | $35.1M | $31.4M | ||
| Q4 24 | $29.0M | $22.1M | ||
| Q3 24 | $60.0M | $35.8M | ||
| Q2 24 | $69.1M | $28.6M | ||
| Q1 24 | $55.3M | $22.2M |
| Q4 25 | $24.6M | $24.1M | ||
| Q3 25 | $47.2M | $33.1M | ||
| Q2 25 | $25.0M | $30.2M | ||
| Q1 25 | $24.4M | $30.3M | ||
| Q4 24 | $16.6M | $21.5M | ||
| Q3 24 | $46.2M | $35.1M | ||
| Q2 24 | $63.1M | $28.2M | ||
| Q1 24 | $46.5M | $21.2M |
| Q4 25 | 13.4% | 19.3% | ||
| Q3 25 | 24.6% | 26.8% | ||
| Q2 25 | 14.3% | 25.2% | ||
| Q1 25 | 14.3% | 24.9% | ||
| Q4 24 | 8.9% | 18.1% | ||
| Q3 24 | 24.1% | 30.3% | ||
| Q2 24 | 34.6% | 25.4% | ||
| Q1 24 | 27.1% | 19.1% |
| Q4 25 | 4.5% | 0.6% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.9% | ||
| Q4 24 | 6.7% | 0.5% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 5.1% | 0.9% |
| Q4 25 | 1.35× | 0.15× | ||
| Q3 25 | 3.03× | 3.55× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
